OMass Therapeutics: The 21st Century Vertex?

Published

April 29, 2022

OMass Therapeutics: The 21st Century Vertex?

Originally spun out of Oxford University, biotech firm OMass Therapeutics today completed an impressive
$100m series B round. CEO Ros Deegan, one of In Vivo’s 2022 rising leaders, believes the firm’s proprietary technology platform, which is based on mass spectrometry, could open the door to an innovative approach to drug discovery…

MORERelated News
Ros Deegan: Always up for a new challenge: How Ros carved out a path to lead her own company
Always up for a new challenge, Ros describes the many twists and turns her career has taken over the years....
Lab crunch: British science has nowhere to go
OXFORD, England, June 20 (Reuters) - For Ros Deegan, the thrill of raising $100 million to expand a biotech firm...
Native mass spectrometry: Drug discovery’s new kid on the block
Current drug discovery methods have limited success against certain drug targets and better approaches are needed. Professor Dame Carol Robinson’s...